Compare Sunrun Inc (RUN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance

Sunrun (RUN) trades at $7.79, up 2.64% on the day, but remains in a bearish technical trend with strong selling pressure in moving averages. The stock shows attractive valuation metrics with P/E of 5.3 and P/B of 0.54, while consistently beating earnings expectations in recent quarters. Recent developments include a record 580 MW grid dispatch with Tesla and expanded partnerships for distributed computing solutions.

Despite positive analyst sentiment (62% buy ratings) and a $15.40 consensus price target representing 98% upside, RUN faces significant headwinds including negative operating cash flow, high debt levels (70.76% debt-to-asset ratio), and solar industry pressure from elevated borrowing costs. The stock trades near its analyst low target of $7.00, suggesting limited downside but requiring careful risk assessment.

SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.

Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.